Nanotechnology for Pediatric Retinoblastoma Therapy.
cancer
conventional chemotherapy
nanomedicine
nanoparticle
pediatric rare disease
retinoblastoma
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
31 Aug 2022
31 Aug 2022
Historique:
received:
05
08
2022
revised:
26
08
2022
accepted:
27
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Retinoblastoma is a rare, sometimes hereditary, pediatric cancer. In high-income countries this disease has a survival rate approaching 100%, while in low- and middle-income countries the prognosis is fatal for about 80% of cases. Depending on the stage of the disease, different therapeutic protocols are applied. In more advanced forms of the disease, surgical removal of the entire globe and its intraocular contents (enucleation) is, unfortunately, necessary, whereas in other cases, conventional chemotherapy is normally used. To overcome the side-effects and reduced efficacy of traditional chemotherapic drugs, nanodelivery systems that ensure a sustained drug release and manage to reach the target site have more recently been developed. This review takes into account the current use and advances of nanomedicine in the treatment of retinoblastoma and discusses nanoparticulate formulations that contain conventional drugs and natural products. In addition, future developments in retinoblastoma treatment are discussed.
Identifiants
pubmed: 36145308
pii: ph15091087
doi: 10.3390/ph15091087
pmc: PMC9504930
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Biophotonics. 2019 Nov;12(11):e201900193
pubmed: 31297950
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Invest Ophthalmol Vis Sci. 2021 Nov 1;62(14):13
pubmed: 34784412
Int J Pharm. 2020 Nov 15;589:119824
pubmed: 32861768
Eye (Lond). 2022 Jan 5;:
pubmed: 34987197
Nanomaterials (Basel). 2021 Nov 10;11(11):
pubmed: 34835785
J Ophthalmic Vis Res. 2022 Jan 21;17(1):58-68
pubmed: 35194497
Nihon Yakurigaku Zasshi. 2018;152(6):306-318
pubmed: 30531102
Adv Funct Mater. 2018 Dec 27;28(52):
pubmed: 32699541
Jpn J Cancer Res. 1987 Aug;78(8):858-68
pubmed: 3115934
PLoS One. 2018 May 23;13(5):e0197081
pubmed: 29791475
Nanomedicine. 2007 Mar;3(1):20-31
pubmed: 17379166
Drug Deliv. 2016 Sep;23(7):2488-2496
pubmed: 25758593
Ophthalmology. 2014 Jul;121(7):1453-60
pubmed: 24656794
Anticancer Res. 2020 Sep;40(9):4961-4968
pubmed: 32878784
Cancer Discov. 2016 Apr;6(4):353-67
pubmed: 26658964
Am J Ophthalmol. 2014 Nov;158(5):875-91
pubmed: 25065496
Retina. 2002 Dec;22(6):707-10
pubmed: 12476095
Nature. 1986 Oct 16-22;323(6089):643-6
pubmed: 2877398
Cancer Lett. 2016 Sep 28;380(1):10-9
pubmed: 27319373
Nat Rev Dis Primers. 2015 Aug 27;1:15021
pubmed: 27189421
Br J Ophthalmol. 2016 Feb;100(2):172-8
pubmed: 26061162
Int Ophthalmol Clin. 2011 Winter;51(1):77-91
pubmed: 21139478
ACS Appl Mater Interfaces. 2020 Feb 5;12(5):5642-5657
pubmed: 31940169
Curr Cancer Drug Targets. 2002 Sep;2(3):227-42
pubmed: 12188909
Mol Pharm. 2019 Sep 3;16(9):4045-4058
pubmed: 31361499
Ophthalmology. 2007 Jul;114(7):1378-83
pubmed: 17613328
ACS Nano. 2018 Aug 28;12(8):7482-7496
pubmed: 30071163
ACS Biomater Sci Eng. 2022 Jan 10;8(1):151-160
pubmed: 34933546
Transl Vis Sci Technol. 2019 Sep 27;8(5):18
pubmed: 31602343
Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):787-800
pubmed: 6547421
Macromol Biosci. 2022 Feb;22(2):e2100349
pubmed: 34735739
Toxicol Rep. 2015 May 16;2:758-764
pubmed: 28962411
Nat Rev Mol Cell Biol. 2013 May;14(5):297-306
pubmed: 23594950
Lancet. 2012 Apr 14;379(9824):1436-46
pubmed: 22414599
Pharmaceutics. 2017 Apr 18;9(2):
pubmed: 28420213
Int J Nanomedicine. 2012;7:2389-98
pubmed: 22661892
Prog Retin Eye Res. 2010 Nov;29(6):596-609
pubmed: 20826225
Mol Biol Rep. 2021 Jan;48(1):915-925
pubmed: 33409716
Environ Sci Pollut Res Int. 2022 Jun;29(29):43732-43744
pubmed: 35441996
Drug Deliv. 2022 Dec;29(1):1785-1799
pubmed: 35642917
Int J Pharm. 2012 Aug 1;432(1-2):99-104
pubmed: 22569231
Exp Eye Res. 2021 Mar;204:108423
pubmed: 33453276
Drug Deliv. 2020 Dec;27(1):358-366
pubmed: 32091275
Arch Ophthalmol. 1981 Oct;99(10):1763-6
pubmed: 7295123
Clin Transl Oncol. 2022 Sep;24(9):1682-1701
pubmed: 35612653
Front Oncol. 2022 Apr 01;12:822330
pubmed: 35433448
Nat Commun. 2022 Aug 10;13(1):4689
pubmed: 35948546
J Clin Oncol. 2012 Apr 1;30(10):1034-41
pubmed: 22370329
Pharmaceutics. 2019 Jul 24;11(8):
pubmed: 31344882
ACS Nano. 2017 May 23;11(5):4669-4685
pubmed: 28463509
Curr Opin Ophthalmol. 2010 May;21(3):203-12
pubmed: 20224400
IET Nanobiotechnol. 2017 Feb;11(1):18-23
pubmed: 28476956
Mol Ther Nucleic Acids. 2017 Dec 15;9:349-364
pubmed: 29246314
Ophthalmology. 2011 Oct;118(10):2081-7
pubmed: 21715012
Mater Sci Eng C Mater Biol Appl. 2017 Jul 1;76:646-651
pubmed: 28482574
Ophthalmology. 2008 Aug;115(8):1398-404, 1404.e1
pubmed: 18342944
Ophthalmology. 2014 May;121(5):1109-18
pubmed: 24589388
Arch Dis Child. 1999 Feb;80(2):171-4
pubmed: 10325735
Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1696-1705
pubmed: 31009525
Mol Vis. 2013 May 06;19:1029-38
pubmed: 23687439
Drug Deliv. 2022 Dec;29(1):519-533
pubmed: 35156504
J Cancer Res Ther. 2020 Jul-Sep;16(4):708-712
pubmed: 32930107
Br J Ophthalmol. 2019 Apr;103(4):488-493
pubmed: 29875233
J Virol. 2015 May;89(9):5012-21
pubmed: 25694602
Nanomedicine (Lond). 2007 Feb;2(1):11-21
pubmed: 17716187
Crit Rev Biotechnol. 2018 Nov;38(7):1003-1024
pubmed: 29402135
Invest New Drugs. 2021 Apr;39(2):426-441
pubmed: 33200242
Pharm Res. 2018 Jan 3;35(1):11
pubmed: 29299768
Cancer Treat Rev. 2016 Apr;45:129-38
pubmed: 27017286
Arch Ophthalmol. 2011 Jun;129(6):732-7
pubmed: 21320950
Indian J Ophthalmol. 2014 May;62(5):585-9
pubmed: 24881606
Macromol Biosci. 2012 May;12(5):608-20
pubmed: 22508445
JAMA Oncol. 2020 May 1;6(5):685-695
pubmed: 32105305
J Funct Biomater. 2015 Apr 30;6(2):277-98
pubmed: 25941990
Drug Deliv. 2022 Dec;29(1):1914-1932
pubmed: 35748543
Lancet Oncol. 2014 Sep;15(10):1157-67
pubmed: 25126964
J Control Release. 2019 Mar 28;298:177-185
pubmed: 30776396
Am J Ophthalmol. 2014 May;157(5):1109-15
pubmed: 24503408
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9
pubmed: 23264323
J Biomed Nanotechnol. 2008 Dec 1;4(4):410-418
pubmed: 20668648
JAMA. 1997 Oct 15;278(15):1262-7
pubmed: 9333268
Lancet Glob Health. 2022 Mar;10(3):e380-e389
pubmed: 35093202
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207175
Int J Biol Macromol. 2014 Sep;70:572-82
pubmed: 25088498
Trans Am Acad Ophthalmol Otolaryngol. 1963 Mar-Apr;67:164-72
pubmed: 13973597
Semin Oncol. 2017 Dec;44(6):385-394
pubmed: 29935900
Sci Transl Med. 2019 Jan 23;11(476):
pubmed: 30674657
AORN J. 2020 Jan;111(1):69-79
pubmed: 31886534
Asian J Pharm Sci. 2020 Sep;15(5):558-575
pubmed: 33193860